GE Licenses IP to Cellular Dynamics Enabling iPS Cell Assay, Model Development | GenomeWeb

NEW YORK (GenomeWeb News) – GE Healthcare Life Sciences and Cellular Dynamics today announced a licensing deal allowing CDI to develop, manufacture, and sell cellular assays and models derived from induced pluripotent stem cells for drug discovery and toxicity screening.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.